09:12 AM EDT, 05/22/2026 (MT Newswires) -- Health care stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF ( XLV ) 0.6% higher and the iShares Biotechnology ETF (IBB) down 0.1%.

Biogen (BIIB) and Denali Therapeutics ( DNLI ) are discontinuing further development of BIIB122 in idiopathic Parkinson's disease after a phase 2b study failed to meet its primary or secondary endpoints, the companies said. Biogen shares were down 1% and Denali Therapeutics ( DNLI ) stock lost more than 3% pre-bell.

Medline (MDLN) shares were up more than 1% after the company priced its upsized secondary offering of about 72.6 million of its class A shares on behalf of certain selling stockholders at $37 apiece.

Gilead Sciences ( GILD ) said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion supporting approval of Trodelvy as a first-line treatment for certain patients with metastatic triple-negative breast cancer. Gilead Sciences ( GILD ) shares were 0.4% higher pre-bell.